Dr. P felt he was more important than Leronlimab, he wanted the success tone about him and not about LL. He was viewing CytoDyn as a way to sell himself, not to sell our molecule. So as opposed to looking for new ways to use LL, he was looking for new ways to better his position.

This is a problem for shareholder's who are in the business of selling LL, not in the business of selling Dr. P., it didn’t have to be but there is a very big ego in the way of making a collaboration a success.